The ESMO Gynaecological Cancers Congress 2025 programme is online!
The ESMO Gynaecological Cancers Congress 2025 will provide insights into the diagnosis, biology and therapy of gynaecological malignancies.
Specifically, the Congress will include educational and scientific sessions covering:
- Practice-changing progress in the treatment of patients with gynaecological cancers
- Recent developments in therapies integrating PARP inhibitors, targeted agents and ADCs for managing patients with ovarian cancer
- State-of-the-art in diagnosis and management of cervical and endometrial cancers
- Bench to bedside research perspectives in gynaecological oncology
- Novel therapeutic strategies for rare gynaecological cancers
Learning objectives
- To provide updates on state-of-the-art management of patients with gynaecological cancers
- To highlight the scientific advances in profiling, risk stratification and therapeutic options for the optimal care of patients with gynaecological cancers
- To highlight biomarkers applicable for precision medicine in patients with gynaecological cancers
Accreditation
ESMO-MORA: The Congress programme will be submitted for ESMO-MORA category 1. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
Disclaimer
ESMO is a scientific and professional, non-political and non-religious organisation. ESMO will not accept responsibility for any comments or remarks made during any of our events by session chairs, invited speakers, presenters, members or any other contributor, formally or informally, which might cause offence or be perceived as being biased.
The experts invited by ESMO as abstract Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.